{"protocolSection": {"identificationModule": {"nctId": "NCT00394654", "orgStudyIdInfo": {"id": "MI-CP138"}, "secondaryIdInfos": [{"id": "NCT00394654", "type": "REGISTRY", "domain": "ClinicalTrials.gov"}], "organization": {"fullName": "MedImmune LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma", "officialTitle": "A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma"}, "statusModule": {"statusVerifiedDate": "2013-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-11"}, "primaryCompletionDateStruct": {"date": "2007-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-10-31", "studyFirstSubmitQcDate": "2006-10-31", "studyFirstPostDateStruct": {"date": "2006-11-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-10-18", "resultsFirstSubmitQcDate": "2013-10-18", "resultsFirstPostDateStruct": {"date": "2013-12-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-10-18", "lastUpdatePostDateStruct": {"date": "2013-12-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "MedImmune LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a Phase 2a, randomized multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma.", "detailedDescription": "This study (MI-CP138) is a Phase 2a, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma. Approximately three investigative sites in Canada will participate in this study, with up to 40 evaluable patients randomized in a 1:1 ratio to receive MEDI-528 (9.0 mg/kg) or placebo as a single IV infusion."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MEDI528 9 mg/kg", "type": "EXPERIMENTAL", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion", "interventionNames": ["Biological: MEDI-528 9 mg/kg"]}, {"label": "PLACEBO", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered as a single intravenous infusion", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "MEDI-528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion", "armGroupLabels": ["MEDI528 9 mg/kg"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo administered as a single intravenous infusion", "armGroupLabels": ["PLACEBO"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7", "description": "Change from baseline (percent reduction) in mean maximum decline of forced expiratory volume in one second (FEV1) during LAR at 3 to 7 hours after an inhaled allergen challenge.", "timeFrame": "Day 7"}, {"measure": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28", "description": "Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "timeFrame": "Day 28"}, {"measure": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56", "description": "Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "timeFrame": "Day 56"}, {"measure": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 7", "description": "Change from baseline (percent reduction) in mean maximum decline of area under the concentration-time curve (AUC) of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "timeFrame": "Day 7"}, {"measure": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28", "description": "Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "timeFrame": "Day 28"}, {"measure": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56", "description": "Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "timeFrame": "Day 56"}], "secondaryOutcomes": [{"measure": "Incidence of Adverse Events", "description": "Number of participants experiencing adverse events (includes both adverse events and serious adverse events)", "timeFrame": "Days 0 - 126"}, {"measure": "Incidence of Serious Adverse Events", "description": "Number of participants experiencing serious adverse events", "timeFrame": "Days 0 - 126"}, {"measure": "Incidence of Anti-drug Antibodies (ADA) to MEDI-528", "description": "Number of participants with ADA to MEDI-528", "timeFrame": "Days 0, 27, 55, 84, and 126"}, {"measure": "Time to Observed Maximum Serum Concentration (Tmax)", "description": "Tmax of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}, {"measure": "Time to Observed Maximum Sputum Concentration (Tmax)", "description": "Tmax of MEDI-528 in sputum", "timeFrame": "Days -21 to -7, 7, 28, and 56"}, {"measure": "Time to Observed Maximum Nasal Lavage Concentration (Tmax)", "description": "Tmax of MEDI-528 in nasal lavage", "timeFrame": "Days -6 to -1, 8, 29, and 57"}, {"measure": "Observed Maximum Serum Concentration (Cmax)", "description": "Cmax of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}, {"measure": "Observed Maximum Sputum Concentration (Cmax)", "description": "Cmax of MEDI-528 in sputum", "timeFrame": "Days -21 to -7, 7, 28, and 56"}, {"measure": "Observed Maximum Nasal Lavage Concentration (Cmax)", "description": "Cmax of MEDI-528 in nasal lavage", "timeFrame": "Days -6 to -1, 8, 29, and 57"}, {"measure": "Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]", "description": "AUC(0-t) of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}, {"measure": "Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]", "description": "AUC(0-t) of MEDI-528 in sputum", "timeFrame": "Days -21 to -7, 7, 28, and 56"}, {"measure": "Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]", "description": "AUC(0-t) of MEDI-528 in nasal lavage", "timeFrame": "Days -6 to -1, 8, 29, and 57"}, {"measure": "Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]", "description": "AUC(0-infinity) of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}, {"measure": "Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]", "description": "AUC(0-infinity) of MEDI-528 in sputum", "timeFrame": "Days -21 to -7, 7, 28, and 56"}, {"measure": "Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]", "description": "AUC(0-infinity) of MEDI-528 in nasal lavage", "timeFrame": "Days -6 to -1, 8, 29, and 57"}, {"measure": "Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]", "description": "AUC(ext) of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}, {"measure": "Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]", "description": "AUC(ext) of MEDI-528 in sputum", "timeFrame": "Days -21 to -7, 7, 28, and 56"}, {"measure": "Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]", "description": "AUC(ext) of MEDI-528 in nasal lavage", "timeFrame": "Days -6 to -1, 8, 29, and 57"}, {"measure": "Terminal Phase Half-Life (T1/2)", "description": "T1/2 of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}, {"measure": "Terminal Phase Half-Life (T1/2)", "description": "T1/2 of MEDI-528 in sputum", "timeFrame": "Days -21 to -7, 7, 28, and 56"}, {"measure": "Terminal Phase Half-Life (T1/2)", "description": "T1/2 of MEDI-528 in nasal lavage", "timeFrame": "Days -6 to -1, 8, 29, and 57"}, {"measure": "Total Body Clearance (CL)", "description": "CL of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}, {"measure": "Terminal Phase Volume of Distribution (Vz)", "description": "Vz of MEDI-528 in serum", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adults, age 18 through 65 years of age at the time of screening;\n* Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures;\n* Previously documented diagnosis of asthma of \\> 1 year duration, based on episodic symptoms of airflow obstruction, at least partial reversibility of airflow obstruction, with alternative diagnoses (e.g., chronic obstructive pulmonary disease) ruled out;\n* AHR in the methacholine challenge test with a PC20 (provoking concentration of methacholine to cause a 20% fall in FEV1) \u2264 16 mg/mL (Crapo, 2000);\n* Have dual response of EAR, defined as a decrease in FEV1 \u2265 20% at 0 to 3 hours after inhalation, and LAR, defined as a decrease in FEV1 \u2265 15% 3 to 7 hours after inhalation, to inhaled allergen;\n* Asthma symptoms are adequately controlled on short-acting \u03b22 agonists (e.g., albuterol) alone;\n* Have had no significant changes in regular asthma medications and no acute asthma exacerbations requiring corticosteroid rescue, hospitalization, or emergency department visits for at least 4 weeks prior to screening and up through the time of the first dose of study drug on Study Day 0.\n* Sexually active women, unless surgically sterile or at least 1 year post-menopausal, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, intrauterine device, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 21 days prior to the first dose of study drug on Study Day 0, and must agree to continue using such precautions through Study Day 126. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active men, unless surgically sterile, must likewise use an effective method of birth control (condom) and must agree to continue using such precautions through Study Day 126;\n* Able to complete the follow-up period through Study Day 126, as required by the protocol.\n* Willing to forego other forms of experimental treatment and study procedures during the study; and\n* Able to provide spirometric readings that meet American Thoracic Society (ATS) standards (ATS, 1995).\n\nExclusion Criteria:\n\n* Receipt of MEDI-528 in any previous clinical study;\n* History of allergy or adverse reactions to any component of the MEDI-528 formulation;\n* Lung disease other than allergic asthma (e.g. chronic bronchitis);\n* Current use of any systemic or inhaled immunosuppressive drugs, including systemic and inhaled corticosteroids (topical corticosteroids are permitted), long-acting \u03b22 agonists, leukotriene antagonists, cromolyn sodium, nedocromil sodium, theophylline or any inhaled or systemic medication for asthma other than short-acting \u03b22 agonists, for at least 4 weeks prior to study drug administration on Study Day 0.\n* Current use of any \u03b2-adrenergic antagonist (e.g. propranolol).\n* Any disease or illness, other than asthma, that may require the use of systemic corticosteroids during the study period.\n* Acute illnesses or evidence of clinically significant active infection, such as fever \u00b3 38.0\u00b0C (100.5\u00b0F) at screening and through the time of the study drug administration on Study Day 0;\n* Current allergy-vaccination therapy (i.e., desensitization immunotherapy) with less than 3 months of stable maintenance doses prior to the baseline allergen inhalation challenge;\n* Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to the first dose of study drug through Study Day 150;\n* Receipt of any therapy with a leukocyte-depleting agent unless recovery in white cell count has been documented before screening;\n* Pregnancy (sexually active females must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to study drug administration on Study Day 0);\n* Is a nursing mother at the time of study enrollment;\n* Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active infection with hepatitis A;\n* History of significant systemic disease (e.g., cancer; infection; coronary artery disease or other cardiovascular disease; or hematological, renal, hepatic, endocrinologic, neurologic, rheumatologic, or gastrointestinal disease);\n* History of cancer other than nonmelanoma skin cancer or cervical carcinoma-in-situ that have been treated successfully with curative therapy;\n* History of primary immunodeficiency;\n* History of pancreatitis;\n* History of use of tobacco products within 2 years of baseline or history of smoking \\>= 10 pack-years;\n* Elective surgery planned from the time of screening through Study Day 126;\n* Clinically significant abnormalities (other than asthma) upon physical examination prior to study drug administration on Study Day 0;\n* Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at the time of screening;\n* At the time of screening, any of the following abnormalities: aspartate transaminase (AST), alanine transaminase (ALT), or amylase \\> 1.5 \u00d7 above the upper limits of normal (ULN); or serum creatinine \\> 1.3 \u00d7 ULN; or any other abnormal laboratory values in the screening panel that, in the opinion of the principal investigator (PI), are judged to be clinically significant; or\n* Evidence of any systemic disease or respiratory disease (other than asthma), any finding upon physical examination or history of any disease that, in the opinion of the PI or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Nestor Molfino, M.D.", "affiliation": "MedImmune LLC", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "McMaster University", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "University of Saskatchewan", "city": "Saskatoon", "state": "Saskatchewan", "zip": "S7N 0W8", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "Hopital Laval", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Treatment assignments were determined using a block randomization procedure with a 1:1 ratio through an interactive Web response system (IWRS). Patients who were randomized into the study but did not complete the second allergen challenge on Day 7 were replaced, unless the patient withdrew for safety reasons.", "recruitmentDetails": "Thirty patients were entered into the study between 16Oct2006 and 15Aug2007 at 2 sites in Canada.", "groups": [{"id": "FG000", "title": "PLACEBO"}, {"id": "FG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "PARTICIPANT LEFT STDUY REGION", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "PLACEBO"}, {"id": "BG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "30"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30.5", "spread": "9.6"}, {"groupId": "BG001", "value": "26.5", "spread": "7.8"}, {"groupId": "BG002", "value": "28.5", "spread": "8.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7", "description": "Change from baseline (percent reduction) in mean maximum decline of forced expiratory volume in one second (FEV1) during LAR at 3 to 7 hours after an inhaled allergen challenge.", "populationDescription": "All participants who were randomized into the study and completed the second allergen challenge on Day 7.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Day 7", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.26", "spread": "69.288"}, {"groupId": "OG001", "value": "-16.21", "spread": "61.788"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.168", "statisticalMethod": "Univariate 2-sample t-test"}]}, {"type": "PRIMARY", "title": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28", "description": "Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "populationDescription": "All participants who were randomized into the study and completed the second allergen challenge on Day 7.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Day 28", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.93", "spread": "46.646"}, {"groupId": "OG001", "value": "-16.95", "spread": "123.256"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.254", "statisticalMethod": "Univariate 2-sample t-test"}]}, {"type": "PRIMARY", "title": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56", "description": "Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "populationDescription": "All participants who were randomized into the study and completed the second allergen challenge on Day 7.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Day 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.36", "spread": "45.123"}, {"groupId": "OG001", "value": "31.85", "spread": "53.709"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.677", "statisticalMethod": "Univariate 2-sample t-test"}]}, {"type": "PRIMARY", "title": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 7", "description": "Change from baseline (percent reduction) in mean maximum decline of area under the concentration-time curve (AUC) of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "populationDescription": "All participants who were randomized into the study and completed the second allergen challenge on Day 7.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Day 7", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.86", "spread": "94.34"}, {"groupId": "OG001", "value": "-14.47", "spread": "82.43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.318", "statisticalMethod": "Univariate 2-sample t-test"}]}, {"type": "PRIMARY", "title": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28", "description": "Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "populationDescription": "All participants who were randomized into the study and completed the second allergen challenge on Day 7.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Day 28", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.91", "spread": "133.75"}, {"groupId": "OG001", "value": "-13.09", "spread": "175.27"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.798", "statisticalMethod": "Univariate 2-sample t-test"}]}, {"type": "PRIMARY", "title": "Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56", "description": "Change from baseline (percent reduction) in mean maximum decline of AUC of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.", "populationDescription": "All participants who were randomized into the study and completed the second allergen challenge on Day 7.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent", "timeFrame": "Day 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.75", "spread": "65.49"}, {"groupId": "OG001", "value": "51.91", "spread": "98.49"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.766", "statisticalMethod": "Univariate 2-sample t-test"}]}, {"type": "SECONDARY", "title": "Incidence of Adverse Events", "description": "Number of participants experiencing adverse events (includes both adverse events and serious adverse events)", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days 0 - 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Incidence of Serious Adverse Events", "description": "Number of participants experiencing serious adverse events", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days 0 - 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Incidence of Anti-drug Antibodies (ADA) to MEDI-528", "description": "Number of participants with ADA to MEDI-528", "populationDescription": "All subjects who received at least one dose of investigational product (MEDI-528 or placebo)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Days 0, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Time to Observed Maximum Serum Concentration (Tmax)", "description": "Tmax of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Day", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "0.028", "spread": "20.4"}]}]}]}, {"type": "SECONDARY", "title": "Time to Observed Maximum Sputum Concentration (Tmax)", "description": "Tmax of MEDI-528 in sputum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Day", "timeFrame": "Days -21 to -7, 7, 28, and 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "9.276", "spread": "99"}]}]}]}, {"type": "SECONDARY", "title": "Time to Observed Maximum Nasal Lavage Concentration (Tmax)", "description": "Tmax of MEDI-528 in nasal lavage", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Day", "timeFrame": "Days -6 to -1, 8, 29, and 57", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "10.319", "spread": "169.6"}]}]}]}, {"type": "SECONDARY", "title": "Observed Maximum Serum Concentration (Cmax)", "description": "Cmax of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Microgram per milliliter", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "229.672", "spread": "18.1"}]}]}]}, {"type": "SECONDARY", "title": "Observed Maximum Sputum Concentration (Cmax)", "description": "Cmax of MEDI-528 in sputum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram per milliliter", "timeFrame": "Days -21 to -7, 7, 28, and 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "71.843", "spread": "78.7"}]}]}]}, {"type": "SECONDARY", "title": "Observed Maximum Nasal Lavage Concentration (Cmax)", "description": "Cmax of MEDI-528 in nasal lavage", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram per milliliter", "timeFrame": "Days -6 to -1, 8, 29, and 57", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "79.406", "spread": "136.6"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]", "description": "AUC(0-t) of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Microgram times day per milliliter", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "5744.821", "spread": "14.8"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]", "description": "AUC(0-t) of MEDI-528 in sputum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram times day per milliliter", "timeFrame": "Days -21 to -7, 7, 28, and 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "2382.123", "spread": "84"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]", "description": "AUC(0-t) of MEDI-528 in nasal lavage", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram times day per milliliter", "timeFrame": "Days -6 to -1, 8, 29, and 57", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "1332.408", "spread": "147.6"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]", "description": "AUC(0-infinity) of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Microgram times day per milliliter", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "6224.272", "spread": "17"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]", "description": "AUC(0-infinity) of MEDI-528 in sputum", "populationDescription": "All participants who were randomized, received any MEDI-528, and had sputum samples obtained", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram times day per milliliter", "timeFrame": "Days -21 to -7, 7, 28, and 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "4136.234", "spread": "61.9"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)]", "description": "AUC(0-infinity) of MEDI-528 in nasal lavage", "populationDescription": "All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram times day per milliliter", "timeFrame": "Days -6 to -1, 8, 29, and 57", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "6047.098", "spread": "134"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]", "description": "AUC(ext) of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Percent", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "6.441", "spread": "59.3"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]", "description": "AUC(ext) of MEDI-528 in sputum", "populationDescription": "All participants who were randomized, received any MEDI-528, and had sputum samples obtained", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Percent", "timeFrame": "Days -21 to -7, 7, 28, and 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "25.919", "spread": "81.3"}]}]}]}, {"type": "SECONDARY", "title": "Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]", "description": "AUC(ext) of MEDI-528 in nasal lavage", "populationDescription": "All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Percent", "timeFrame": "Days -6 to -1, 8, 29, and 57", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "18.848", "spread": "178.3"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Phase Half-Life (T1/2)", "description": "T1/2 of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Day", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "34.316", "spread": "20.8"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Phase Half-Life (T1/2)", "description": "T1/2 of MEDI-528 in sputum", "populationDescription": "All participants who were randomized, received any MEDI-528, and had sputum samples obtained", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Day", "timeFrame": "Days -21 to -7, 7, 28, and 56", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "31.933", "spread": "83.1"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Phase Half-Life (T1/2)", "description": "T1/2 of MEDI-528 in nasal lavage", "populationDescription": "All participants who were randomized, received any MEDI-528, and had nasal lavage samples obtained", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Day", "timeFrame": "Days -6 to -1, 8, 29, and 57", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "25.584", "spread": "69"}]}]}]}, {"type": "SECONDARY", "title": "Total Body Clearance (CL)", "description": "CL of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter per day", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "0.101", "spread": "26.7"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Phase Volume of Distribution (Vz)", "description": "Vz of MEDI-528 in serum", "populationDescription": "All participants who were randomized and received any MEDI-528", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter", "timeFrame": "Days 0, 6, 7, 27, 55, 84, and 126", "groups": [{"id": "OG000", "title": "PLACEBO", "description": "Placebo administered as a single intravenous (IV) infusion"}, {"id": "OG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "5.025", "spread": "23.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "PLACEBO", "seriousNumAffected": 1, "seriousNumAtRisk": 15, "otherNumAffected": 11, "otherNumAtRisk": 15}, {"id": "EG001", "title": "MEDI528 9 mg/kg", "description": "MEDI-528 at a single dose of 9 mg/kg administered as an IV infusion", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 12, "otherNumAtRisk": 15}], "seriousEvents": [{"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}], "otherEvents": [{"term": "Lacrimation increased", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Enteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Chills", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Chlamydial infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Vaginal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Blood bicarbonate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Blood potassium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 15}]}, {"term": "Haemoglobin decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Lymphocyte count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Neutrophil count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Protein urine present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 15}]}, {"term": "White blood cell count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication."}, "pointOfContact": {"title": "Don Raible, MD", "organization": "MedImmune", "email": "raibleD@medimmune.com", "phone": "301-398-0000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}